StemCell Therapy

The basic principles of homeopathy, and its legal and scientific foundations, are discussed in an overview to address the positions of the World Health Organization (WHO) and the commission of the European Union (EU) on complementary medicine. According to the WHO,the antimicrobial resistance problem poses aglobal threat. The EU Commissions current One Health Action Plan requests research in complementary medicine, the WHO urges member states to include complementary medicine in their national health policies. Regarding external evidence on the general use of human and veterinary homeopathy, evidence level 1a studies are reviewed. Focusing on the external evidence on the use of homeopathy in infections, some evidence level 1a, 1b, 2c studies, and a case report, are described in more detail. In conclusion, evidence for the effectiveness of human and veterinary homeopathy in general, and in particular, of homeopathic treatment for infections, is available. Especially, individualized homeopathy demonstrates effects at all quality levels according to Cochrane criteria, even in the methodologically high-quality studies. As in most areas of veterinary medicine and medicine, further good/excellent studies are necessary. In compliance with the principles of homeopathy, further methodologically high-quality trials focusing on the homeopathic treatment of infections are the next logical step. The selection of the simile (individually fitting homeopathic medicinal product) by appropriately trained homeopathic doctors/veterinarians is essential for the effectiveness of homeopathy. Implementation of studies at university facilities is a prerequisite for quality assurance.Consequently, further integration of homeopathy at universities is a necessary requirement for the patientsbest interests.

PubMed

Link:
[Evidence-based homeopathy and veterinary homeopathy, and its potential to help overcome the anti-microbial resistance problem an overview]. -...

File image.

What are the signs of colic, and what should you do, are among the questions that will be answered in the latest free horse care webinar from World Horse Welfare.

Understanding colic what we as owners need to know at 7pm (GMT) on Wednesday October 7, is being hosted byDr Katie Lightfoot, a Teaching Associate at the University of Nottinghams School of Veterinary Medicine and Science joins World Horse Welfares International Programme Officer Izzy Wild, who is also a vet, and has experience of dealing with complex colic case.

The webinar is part of the charitys Welfare Wednesday series that runs fortnightly.

Katie will explain what owners can do to prepare themselves if their horse gets colic. She will discuss the types of decisions owners may have to make and provide some real-life case studies of owner experiences. Izzy will explain what the main risk factors are and talk through the critical signs owners should be able to recognise and what steps to take.

Both will answer questions at the end of the webinar, and both are keen to share their experiences to ensure owners we are as informed as possible about what happens if their horse gets colic.

The fortnightly webinars are free to attend and they can also be viewed live as a Facebook Live session, but by registering with Zoom you get to take part in the various polls, ask questions during the Q&A and overall have a much more interactive experience.

Register here

About the presenters:

Dr Katie Lightfoot is a Teaching Associate at the University of Nottinghams School of Veterinary Medicine and Science. As part of the equine teaching team, she supports the learning of undergraduate vet students in subjects such as equine welfare, anatomy, and behaviour. Before joining the university, Katie completed a PhD research project which evaluated horse owner behaviour and knowledge transfer in response to an educational campaign.

Izzy Wild graduated from the University of Nottingham as a vet, also undertaking a Research Masters with the Nottingham Colic Project. Following finals, she researched colic in working equids in Honduras at a World Horse Welfare partner-project. She worked in First Opinion equine practice for two years in Hampshire, before joining World Horse Welfare in August, where she is working as an International Programme Officer. Izzy has an interest in veterinary research, education and working equids.

All previous webinars are available to watch on the World Horse Welfare YouTube channel.

xx

Read more:
Free webinar: What horse owners need to know about colic - Horsetalk

When Jeff Pleiss, associate professor of molecular biology and genetics in the College of Arts and Sciences, began studying RNA biology two decades ago, he could not have known that the kind of high-volume RNA analysis his lab performs on single-cell yeast would have any importance in fighting a pandemic.

Pleiss studies rare RNA species in different, changing environments, elucidating pathways in RNA biology that are critical for gene expression in eukaryotes. To do this, he must take cellular mixes and robustly and carefully separate RNA in order to identify different RNA species. Identifying COVID-19 in humans requires similar separation of RNA.

The Cornell COVID-19 Testing Lab, housed in the College of Veterinary Medicines Animal Health Diagnostic Center, had been handling thousands of clinical samples from animals a day. Beginning in August, it adapted and expanded routine testing for COVID-19.

In a typical day, Pleiss lab examines up to 20,000 specimens at a time. When Cornell was faced with the challenge of developing its own testing system, Pleiss stepped forward to offer his labs experience with RNA processing. They use a robotic process to pool specimens to achieve such a high volume. The Cornell COVID-19 Testing Laboratory (CCTL) acquired similar robots, and the Pleiss lab Ph.D. candidate Zach Dwyer helped to write the scripts for the liquid handlers to prepare sample pools.

CCTL is housed in and led by the College of Veterinary Medicines Animal Health Diagnostic Center (AHDC). The AHDC had been handling thousands of clinical samples from animals a day and now was adapting and expanding their routine testing for COVID-19. As a Level 1 laboratory of the National Animal Health Laboratory Network (NAHLN) the center was set up to test 800 to 1,200 samples for animal infectious diseases in one work shift; using robotic liquid handlers with Pleiss input now facilitated the processing of 5,000 to 7,000 tests a day.

Members of the Pleiss lab, which like the AHDC and CCTL use a 96-well format and similar equipment, are looking for ways to further streamline and enhance efficiencies of CCTLs critical work by investigating the possibility of testing larger pools.

The Pleiss lab also has experience using standard, off-the-shelf components for the testing process rather than more expensive commercial kits, which enables them to achieve their high volume of testing in an affordable way. And commercial kits can be subject to global supply limitations, Pleiss said, adding that such kits are like pre-made chocolate chip cookie dough.

Pre-made dough is easy to make into cookies, but package availability may be limited, he said. Sugar and flour and eggs, though, are almost always available, so youll never run out of the components.

With high-volume testing underway at CCTL, Pleiss and his students continue to explore ways that their expertise can support Cornells COVID-19 testing system.

Jeffs lab illustrates how researchers from different fields have mobilized to support Cornell through this pandemic, and how scientists doing foundational, curiosity-driven research can make meaningful contributions to applied problems, said Andrew Bass, the Horace White Professor of Neurobiology and Behavior and senior associate dean in Arts and Sciences.

We are working in parallel with CCTL, staying out of their way while looking for ways to optimize what theyre doing, Pleiss said. The goal is to getthroughput higher and costs even lower, all withoutsacrificing sensitivity.

Kate Blackwood is a writer for the College of Arts and Sciences.

Follow this link:
RNA analysis at heart of COVID-19 testing | Cornell Chronicle - Cornell Chronicle

In the final months before the coronavirus changed all of our lives, Whitwell High School sophomore Grace Moore won three age-group state archery championships in three different states. Known as Grace-E to many of her friends and family, it's only a rumor that the "E" stands for Extraordinary. In truth, her middle name is Elizabeth, hence the "E."

But as amazing as those championships were, as blindingly bright as her future may be in competitive archery, bows and arrows are far from the most extraordinary part of the 15-year-old's story.

"She was six years old," recalled Grace's mother Alison on Monday night. "The doctor told us that without surgery, the Grace we see would not be the Grace we'd keep."

The option the surgeon was offering Jimmy and Alison Moore to rectify Chiari Malformations a rare birth defect where portions of the brain, the cerebellar tonsils, protrude through the bottom opening of the skull into the upper spine, causing pressure on the brain or spinal cord would terrify any parent.

Brain surgery was required. Shaving vertebrae. Removing tissue from the crown of Grace's head to serve as a patch for her brain.

"I'm a nurse, had been for 18 years," said Alison. "And I'd never heard of this. You're told your child has something wrong with their brain and spinal cord. You're terrified."

The seizures started on the 21st day of December in 2011. Grace's speech would be garbled for a few seconds, then return to normal. The first guess by doctors was that she might be having a reaction to some cold medicine. The Moores stopped the medicine. The seizures continued.

"We went to Children's Hospital on Christmas Eve," Alison said. "They did a CT scan that was negative for a brain tumor. We felt better."

But a few days after Christmas they went back for an MRI. She was to be in the machine for 40 to 45 minutes. Medical personnel came back after that time and told Alison and Jimmy they needed 40 minutes more.

"That's when I realized this was serious," said Alison.

It was so serious that the doctor who would ultimately operate on Grace at the Alabama-Birmingham Medical Center, renowned surgeon Jerry Oakes, warned the Moores that there could be dire consequences.

"He told us that Grace could have a stroke, bleed to death, become paralyzed," remembered Alison.

But as they debated the risks, they finally came around to one indisputable fact: "We couldn't bear the thought," said Alison, "that we didn't give her a chance to live a normal life."

So Oakes operated, telling the family the procedure would take 82 minutes. Sure enough, after 82 minutes, he emerged with a bag of Grace's shaved hair, including her ponytail, to let the Moores know all had gone well.

Still, there would be six weeks of rehab and healing at home, with the following instructions from Oakes: "No boxing, no football, no wrestling."

Added Alison: "Mom's restrictions were a little longer."

But for a 6-year-old girl whose older brother Tyler was active in athletics, being banned from contact sports such as softball, volleyball and the like was a major adjustment.

Said Grace: "We're an active family. I wanted to be active, too."

Enter the Marion County 4-H club, which introduced her to archery.

"I picked it up right off the bat," she said. "It's pretty much my life now."

Said Jody Castle, who was the first person to work with Grace through his Castle Outdoors shop in Whitwell: "A normal person will come to my archery range and shoot 12-15 shots. Grace won't quit until she's shot at least 150 to 200 arrows. I've seen her come here and shoot 500 shots over four or five hours. She's just got a passion for it. And she hits the bullseye almost every time."

How passionate has she become on her way to winning Middle School state titles in Georgia, Kentucky and Tennessee, as well as being ranked sixth in her age group nationally?

A few years ago, on the way to her 8th grade winter dance, Grace stopped at Castle's store to shoot a 100 or so arrows. She was already wearing her dress and heels.

"Archery is Grace's platform, her ministry," said Alison. "She's as comfortable around a 5-year-old as a 75-year-old when she's discussing archery. You can just see her glow."

Grace says that glow began about the time she picked up the sport and Tyler now 22 and wrapping up his pre-veterinary medicine degree at the University of Tennessee Knoxville graduated from Whitwell High.

"Tyler always made good grades and was good in sports," Grace said. "When Tyler left, that was my time to flourish. I started making straight A's and winning archery contests."

No one knows where any of this will lead. Her work with 4-H has made her a national shooting sports ambassador. Her archery talents with both the Marion County 4-H team and the Harvest Archery squad in Dayton, Tenn., continue to move her up the national rankings. If her pre-match meals of cheese fries and lemonade keep doing the trick, she may even turn pro at some point.

Maybe then she could pay her parents back for the cost of those four "Robin Hoods" she's collected. For non-archery buffs, a Robin Hood is when you shoot an arrow into the back of another arrow.

"When Grace was starting out, that was fine," said Alison. "Everybody was impressed. But once she got better and those arrows started costing $20 each, I told her that I thought we'd bought enough $40 trophies."

But for Alison, the most priceless moment of the last nine years, a moment that brings the good and the bad of that time full-circle, centers on Tyler, who began riding his bike and distance running as Grace was dealing with her medical issues.

"That was his coping mechanism," said Grace.

All this training eventually led to an Iron Kids event at Harrison Bay State Park, which Tyler won.

"I looked at his time," said Alison. "It was 82 minutes. I said to myself, 'God took care of both of my kids in 82 minutes."

Contact Mark Wiedmer at mwiedmer@timesfreepress.com.

Read the original post:
Wiedmer: Whitwell's Grace Moore doesn't need her bow and arrow to hit your heart - Chattanooga Times Free Press

By Dylan Adams News Editor

Timothy Ray Brown, the first known person to be cured of HIV, died on Sept. 29 at age 54 after battling cancer.

Timothy Ray Brown, a figurehead in the AIDS and HIV community, passed away surrounded by friends after a five-month battle with leukemia, stated Tim Hoeffgen, Browns partner.

Brown received a positive HIV diagnosis in 1995 while studying in Berlin.

In 2006, Brown was diagnosed with acute myeloid leukemia, which is a cancer that builds in the bone marrow and blood interfering with blood cell production. After bouts of infections from several rough rounds of chemotherapy, Browns leukemia came out of remission.

Due to leukemia in his bones, Brown required a stem cell transplant, a process that allows healthy stem cells to be introduced into a host to stimulate the immune system and healthy bone marrow growth. At the time, the survival rates for stem cell transplant were around fifty percent.

Doctors found a match to Browns genetic type, a donor with the CCR5 Delta 32 mutation, a protein that acts as a doorway to stop the HIV from infecting new cells. Three months after Brown stopped taking his HIV medication, doctors found he no longer had HIV in his blood.

After another round of stem cell treatment in February of 2008, Brown went through several near-death complications, almost going blind and becoming paralyzed but slowly recovering. His body was still successfully fighting off HIV.

In July 2012, the Timothy Ray Brown Foundation was created during the World AIDS Conference in Washington, DC. This foundation was built for Brown to show his support and work with medical institutions and scientists to develop a unifying cure and vaccination against HIV.

Brown would often donate large amounts of blood and tissue samples to researchers in the hope of progressing closer towards an HIV cure. According to his partner, Hoeffgen, Tims lifework was to tell his story about his HIV cure and become an ambassador of hope to those in need.

Doctors have since used Brown as a blueprint to work on a potential cure and vaccine for HIV. Most notably for the second person to ever be cured of HIV the London Patient, Adam Castillejo who went through similar stem cell transplants in 2019 before coming forward to the public.

Like Loading...

Related

Read the rest here:
First Man Cured of AIDS Dies From Cancer - The Keystone Newspaper

In 2004, after President George W. Bush cut off all federal funding for embryonic stem-cell research on religious grounds, Californians strongly backed Proposition 71, a $3-billion bond measure to fund this kind of research, even though such funding is usually not the purview of states.

Supporters of the proposition including this editorial board believed it would allow California to stand out as a leader in this field, advance a budding avenue of research that might save lives and alleviate suffering, bolster its biotech sector and fund possible blockbuster treatments that might earn the state royalties as well. Embryonic stem cells are particularly valuable to research because they are undifferentiated, meaning they do not have a particular function, and researchers could conceivably turn them into specialized cells in order to regenerate human cells and tissue.

In the years since, Proposition 71 gave rise to a burst of scientific discovery. Two cancer treatments it helped fund, for blood and bone-marrow cancers, have been approved by the FDA, though neither of those employed embryonic stem cells and could have been funded even under Bush administration rules. It has also supported promising advances in the treatment of diabetes, bubble boy immune deficiency and vision-robbing retinitis pigmentosa, but other efforts have fallen short in clinical trials.

Moreover, the money helped build laboratories and other infrastructure that give California a head start on research and development, making the state the it place for stem-cell research. Researchers in the state moved to the head of the pack for private grants, because projects are less likely to need the time and money to create facilities before work can begin.

Now that Proposition 71 funding has practically run out, the issue is back on the November ballot with Proposition 14, which seeks nearly double the amount worth of bonds $5.5 billion to continue the juggernaut.

This time, voters should reject the measure, with the caveat that the issue could be reconsidered in a couple of years, if its proponents bring it back in better-designed and more modest form and if there are more successes in human trials and financial payback.

We have long had reservations about how the California Institute for Regenerative Medicine, established as a result of Proposition 71, was set up. Though funded publicly, it is not overseen by the governor and Legislature like other state agencies, and its governing board is too large, at 29 members. Those members generally have ties to the advocacy organizations and research institutions that have received most of the money.

The driving force behind the initiative has been Robert N. Klein II, a Bay Area lawyer and real estate investor. There is no doubting Kleins sincerity in his cause. He knows too well the suffering inflicted by intractable diseases; his son Jordan died of complications of Type I diabetes in 2016. His accomplishment in persuading the state to invest billions in a specific avenue of biomedical research has been exceptional.

However, Klein developed these initiatives largely behind closed doors with little to no public input; he has strong ideas about how things should be run on the stem-cell front and has steadfastly resisted more government oversight. Thats fine when hes investing his own money; its a fatal flaw when he is asking voters for nearly $8 billion, the estimated cost of paying off the bonds over time, according to the Legislative Analysts Office.

Kleins role and the bloated structure of CIRMs super-sized governing board have given rise to some serious ethical mishaps, including a board member who improperly intervened to try to get funding for his organization. (He is no longer on the board.) After this and several other examples of impropriety, rules were tightened. Board members must recuse themselves from votes when there is a conflict of interest, but with 29 members who all want certain projects to receive funding, there is too much potential for mutual back-scratching. Instead of repairing this problem, the new proposition would expand CIRMs board to 35 members and retain its troubling independence from oversight by the governor and Legislature, leaving it open to further conflicts of interest.

Proposition 71 hasnt yet yielded a significant financial return on investment for the state or the cures that were ballyhooed at the time. Though no one ever promised quick medical miracles, campaign ads strongly implied they were around the corner if only the funding came through. Proponents oversold the initiatives and voters cant be blamed if they view this new proposal with skepticism.

In the years since Proposition 71 passed, more resources have become available. President Obama reversed Bushs order and restored federal funding, which meant that between CIRM and the National Institutes of Health, along with private grant and investment funding, stem-cell research has been healthy, if not downright flush. That funding has stayed and even grown under President Trump, to more than $2 billion a year, with about $321 million of that in human embryonic stem-cell research. (There have, though, been recent threats to embryonic research from a group of conservative senators.)

The idea was never for California to become the long-term replacement for federal funding. It was to kick-start an industry that would then operate on its own. If that has failed to happen under Proposition 71 as promised, it shouldnt be the responsibility of California taxpayers to fix it. Thats especially true right now, at a time of yawning needs to address the cost of twin health and economic crises and the worsening effects of climate change. Private money for stem cell-work will continue to be available; its not as though research will collapse.

No doubt, the pace of responsible science is incremental and the outcomes uncertain even with the best research efforts. Yet the backers still couch the possibilities in grandiose terms. In a recent interview with the Times editorial board, Klein talked about the money that would be saved by wiping out Alzheimers disease which has so far has frustrated attempts to treat it effectively, despite many billions of dollars in research.

Embryonic stem cell research remains important, and there might be ways in which the state can contribute less grandiose funding while maximizing its investment. For example, scientific research has a well-known valley of death, where many projects cant get funding to make the transition from laboratory to human clinical trials.

Offering some matching help to get projects through that phase might attract businesses and scientists to California, while spending far less than the billions proposed in Proposition 14. Its worth noting that stem-cell work isnt the only kind of research that faces the valley of death problem; its an issue for most basic research that seeks to make the leap to human trials and that might be equally in need of state help.

Now is not the time for a huge new investment in specialized medical research. First, it makes sense to wait until after the election; if Democrats do well, there should be growing support for embryonic stem-cell research at the federal level, which is where such funding should take place. The future of Californias pandemic-battered economy and budget remains to be seen. Waiting also would give voters a chance to find out how well the states stem-cell research projects continue without state dollars, and whether some of the promising advances lead to breakthrough therapies and a return on Californias investment.

There would be an opportunity to rethink and rewrite any future proposals, which should include a far more modest ask of taxpayers as well as fixes to the structure and inflated size of the CIRM board. The institute should also be placed under the same state oversight as other agencies reporting to the governor.

If CIRM needs money for a basic operating budget over the next couple of years, that could be covered by the states general fund. The agency still needs to administer already-funded projects and could use that time to discuss a more affordable path forward. Right now, the state has other, more urgent spending priorities.

Editors note: This newspapers owner, the physician and scientist Dr. Patrick Soon-Shiong, played no role in the editorial boards deliberations on this measure.

See original here:
No on Prop 14: Not the best way to support stem-cell research - Los Angeles Times

Advances in the stem cell therapy sector have been phenomenal over the years. Its assistance in curing humans of various diseases and disorders has generated expansive advancements. These advancements are not just limited to humans. Stem cell therapy has also acquired a prominent place in the veterinary sector.

The influence of animal stem cell therapy for the treatment of various animals for diverse diseases and disorders is growing rapidly. Therefore, this factor may help the global animal stem cell therapy market to generate exponential growth across the forecast period of 2019-2029. Stem cells help in the replacement of neurons affected by stroke, Parkinsons disease, spinal cord injury, Alzheimers disease, and others.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6816

This animal stem cell therapy market report has extensive information on various aspects associated with bringing growth. Important factors such as emerging trends, mergers and acquisitions, and the regional scenario of the animal stem cell therapy market have been analyzed and included in the report. The stakeholders can derive a treasure of information from this report. This report also includes a scrutinized take on the COVID-19 impact on the animal stem cell therapy market.

Animal Stem Cell Therapy Market: Competitive Prospects

The competitive landscape of the animal stem cell therapy market can be described as mildly fragmented. With a considerable chunk of players, the animal stem cell therapy market is surrounded by substantial competition. Research and development activities form an important part of the growth landscape because they help gain novel insights.

Activities such as mergers, acquisitions, joint ventures, collaborations, and partnerships form the foundation of the growth of the animal stem cell therapy market. These activities help manufacturers to gain influence and eventually help in increasing the growth rate of the animal stem cell therapy market. Prominent participants in the animal stem cell therapy market are Magellan Stem Cells, Medivet Biologics LLC, Kintaro Cells Power, U.S. Stem Cell, Inc., Celavet Inc., VETSTEM BIOPHARMA, and VetCell Therapeutics.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=6816&ltype=S

Animal Stem Cell Therapy Market: Key Trends

Infections are scaling up among animals at a rapid rate. The alarming increase is proving fatal for many animals. Therefore, to avoid such incidences and treat existing diseases and disorders, animal stem cell therapy is being applied seamlessly. Hence, this aspect may bring great growth opportunities for the animal stem cell therapy market.

Developments have been observed across the animal stem cell therapy market for long. Autologous adipose-derived mesenchymal stem cells are gaining traction for successfully resolving a range of issues in animals. These stem cells help in treating ligament and tendon injuries to a certain extent. The strengthening influence of this stem cell type in companion animals is also proving to be a prominent growth prospect for the animal stem cell therapy market.

Recent research has also found that stem cell-derived CC exosomes showed improved recovery from myocardial infarction (MI) among pigs. Such developments assure promising growth for the animal stem cell therapy market.

Animal Stem Cell Therapy Market: Regional Analysis

The animal stem cell therapy market is spread across North America, Latin America, the Middle East and Africa, Europe, and Asia Pacific. The animal stem cell therapy market may derive significant growth from North America. The escalating awareness regarding animal stem cell therapy may attract profound growth. Strengthening research and development activities in the region regarding animal stem cell therapy is further expanding the growth prospects.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6816

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

Rohit Bhisey

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

Read more from the original source:
Animal Stem Cell Therapy Market - Great Growth Opportunities for the Market in the Coming Year | TMR Research Study - BioSpace

The FDA has issued (PDF) a complete response letter to Mesoblasts request for approval of allogeneic cell therapy remestemcel-L in children with steroid-resistant graft-versus-host disease. FDA officials want to see data from at least one additional clinical trial before granting full authorization, but Mesoblast is still hoping to snag an accelerated approval using its existing data.

Evidence of the FDAs concerns with Mesoblasts remestemcel-L filing emerged in August when the agency released a briefing document to inform a discussion of the application by the Oncologic Drugs Advisory Committee (ODAC). The FDA cited multiple perceived shortcomings of the filing, arguing for example that the ability of the mesenchymal stem cell therapy to reduce inflammation as measured by inflammatory biomarkers in humans receiving the product has not been demonstrated.

Despite the FDAs concerns, ODAC members voted nine to one that the data support the efficacy of remestemcel-L in children with steroid-resistant graft-versus-host disease. The positive ODAC vote sent shares in Mesoblast, which had been depressed by the briefing document, up 50%.

Inside the COVID-SeroIndex Assay Design and Performance

Join a panel of experts as they discuss the rigor involved in optimizing and scaling a reproducible serological assay for COVID-19.

However, the ODAC vote was advisory, and the FDA, in a rare but far from unprecedented action, has chosen to go against the recommendation of the committee. Shares in Mesoblast fell 37% in response to the rejection, sinking back to the low they hit in the wake of the briefing document.

Mesoblast said the FDA has recommended it runs at least one additional randomized clinical trial in adults or children with steroid-resistant graft-versus-host disease before refiling for approval. The recommendation suggests Mesoblast will need to expend time and money to get remestemcel-L to market. The phase 3 trial cited in the briefing document lasted almost three years.

However, Mesoblast is holding out hope that it can get remestemcel-L to some patients without the extra data requested by the FDA. In light of the unmet medical need, Mesoblast plans to request a Type A meeting with FDA to discuss the possibility of an accelerated approval. Mesoblast is hoping the FDA will agree to authorize remestemcel-L on the proviso that it runs a study post-approval.

If Mesoblast is to persuade the FDA to grant remestemcel-L accelerated approval, it may need to address some of the agencys other concerns. Mesoblast said the FDAs response letter identified the need for further scientific rationale to demonstrate the relationship of potency measurements to the products biologic activity.

The comment reflects sections of the briefing document in which the FDA said the quality attributes lack a demonstrated relationship to the clinical performance of specific [drug product] lots. In the absence of evidence of that relationship, the FDA said the attributes may not be sufficient to ensure the manufacturing process consistently produces remestemcel-L lots of acceptable quality.

In disclosing the response letter, Mesoblast said assays measuring the potency of remestemcel-L will continue to be refined to provide further scientific rationale for its use in severe inflammatory diseases with high mortality risk.

Read this article:
Mesoblast hit by FDA rejection, request to run another trial - FierceBiotech

The current report on Stem Cell Therapy Market covers a comprehensive analysis demonstrating actionable insights for clients. In addition, the report offers business insights that encourage them to take suitable decisions which are likely to leverage their business processes. Moreover, the report is a detailed study exhibiting current market trends with an overview of future market study.

Request Sample copy of this report athttps://www.precisionbusinessinsights.com/request-sample?product_id=15608

Some of the players in the Stem Cell Therapy market include:

Cytori Therapeutics Inc. (U.S.), Fibrocell Science (U.S.), Cellartis AB (Cellectis) (France), BioTime, Inc. (U.S.), GE Healthcare (U.S.), Thermo Fisher Scientific (U.S.), STEMCELL Technologies Inc. (Canada), Fujifilm Holdings Corporation (Japan), Vericel Corporation (Aastrom Bioscience) (U.S.), Brainstorm cell therapeutics (U.S.), and Osiris Therapeutics, Inc. (U.S.) to name a few.

PrecisionBusinessInsights has recently launched a latest report on Stem Cell Therapy Market for its clients. This report offers the clients with factual data validated by industry experts and business heads. The report highly involves chapter wise explanation for every aspect of the market wherein the drivers, trends, opportunities, leading and trending segments are discussed in detail with specific examples. Profiles of leading players are also discussed along with their business expansion strategies.

An overview of the Stem Cell Therapy Market report offers a comprehensive analysis for better reference to understand market competition and analysis throughout the forecast period. It also involves key players and their market performance and current developments. It helps you understand the technical jargons that offer ease and convenience to you in understanding the report contents.

RequestCustomization copy of this report athttps://www.precisionbusinessinsights.com/request-customisation?product_id=15608

Geographical markets are covered separately within the report that includes a competitive analysis on their market performance in the base year as well as predictions for the forecast year. Extensive primary research is conducted to carry out leading information in order to understand the market condition and competition within a specified geography. Comparison between two or multiple geographical markets is carried out effectively to know where to invest in.

Key Features of the Report:

What is the Impact of Covid-19 Outbreak on the Stem Cell Therapy?

About Us:

Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights. We at Precision Business Insights are passionate about market research and love to do the things in an innovative way. Our team is a big asset for us and great differentiating factor. Our company motto is to address client requirements in the best possible way and want to be a part of our client success. We have a large pool of industry experts and consultants served a wide array of clients across different verticals. Relentless quest and continuous endeavor enable us to make new strides in market research and business consulting arena.

Contact Us:

[emailprotected]

PH +1-866-598-1553

See original here:
Stem Cell Therapy Market to Show Incredible Growth by 2025 - The Daily Chronicle

The market research report on the Stem Cell Therapy Market provides a comprehensive analysis of the market dynamics, including development trends, application, types, competitive environment, value chain optimization, and region. Besides this, the report also provides key statistics on the Stem Cell Therapy Market status of the leading market players, key trends, and potential growth opportunities in the market.

The Stem Cell Therapy Market was valued at USD 117.66 Million in 2019 and is projected to reach USD 255.37 Million by 2027, growing at aCAGR of 10.97% from 2020 to 2027.

These study reports are designed with the goal to help the reader in favorable retrieve information and make decisions that are helpful to grow their business. Further, it also provides an examination of the economic synopsis, along with the benefits, drivers, restraints, production, supply, demand, and the level of market growth.

Get a Sample Copy of the Stem Cell Therapy Market Report with Latest Industry Trends @ https://www.verifiedmarketresearch.com/download-sample/?rid=24113

The varying landscape for the overall Stem Cell Therapy industry is offered in the report providing a comprehensive pattern of the Stem Cell Therapy industry and its rapidly changing market landscape. The details mentioned in the report can assist the players in formulating strategies and approaches to gain a robust footing in the industry. Profitable insights and analytical data have been covered in the report to offer insight into global expansion strategies. Each key manufacturer and producer have been thoroughly assessed in the report.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

The market report sheds light on the latest strategic developments and growth patterns of the market players to provide a clear view. The report is an investigative study that provides insights for the players to formulate their business expansion strategies and expand their footing in the market.

1.Stem Cell Therapy Market, By Cell Source:

Adipose Tissue-Derived Mesenchymal Stem Cells Bone Marrow-Derived Mesenchymal Stem Cells Cord Blood/Embryonic Stem Cells Other Cell Sources

2.Stem Cell Therapy Market, By Therapeutic Application:

Musculoskeletal Disorders Wounds and Injuries Cardiovascular Diseases Surgeries Gastrointestinal Diseases Other Applications

3.Stem Cell Therapy Market, By Type:

Allogeneic Stem Cell Therapy Market, By Application Musculoskeletal Disorders Wounds and Injuries Surgeries Acute Graft-Versus-Host Disease (AGVHD) Other Applications Autologous Stem Cell Therapy Market, By Application Cardiovascular Diseases Wounds and Injuries Gastrointestinal Diseases Other Applications

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113

Table of Content:

Market Overview: This is the first section of the report that includes an overview of the scope of products offered in the Stem Cell Therapy market, segments by product and application, and market size.

Market Competition by Player: Here, the report shows how the competition in the Stem Cell Therapy market is growing or decreasing based on deep analysis of market concentrate rate, competitive situations and trends, expansions, merger and acquisition deals, and other subjects. It also shows how different companies are progressing in the Stem Cell Therapy market in terms of revenue, production, sales, and market share.

Company Profiles and Sales Data: This part of the report is very important as it gives statistical as well as other types of analysis of leading manufacturers in the Stem Cell Therapy market. It assesses each and every player studied in the report on the basis of main business, gross margin, revenue, sales, price, competitors, manufacturing base, product specification, product application, and product category.

Market Status and Outlook by Region: The report studies the status and outlook of different regional markets such as Europe, North America, the MEA, Asia Pacific, and South America. All of the regional markets researched about in the report are examined based on price, gross margin, revenue, production, and sales. Here, the size and CAGR of the regional markets are also provided.

Market by Product: This section carefully analyzes all product segments of the Stem Cell Therapy market.

Market by Application: Here, various application segments of the Stem Cell Therapy market are taken into account for research study.

Market Forecast: It starts with revenue forecast and then continues with sales, sales growth rate, and revenue growth rate forecasts of the Stem Cell Therapy market. The forecasts are also provided taking into consideration product, application, and regional segments of the Stem Cell Therapy market.

Upstream Raw Materials: This section includes industrial chain analysis, manufacturing cost structure analysis, and key raw materials analysis of the Stem Cell Therapy market.

Marketing Strategy Analysis, Distributors: Here, the research study digs deep into behavior and other factors of downstream customers, distributors, development trends of marketing channels, and marketing channels such as indirect marketing and direct marketing.

Research Findings and Conclusion: This section is solely dedicated to the conclusion and findings of the research study on the Stem Cell Therapy market.

Appendix: This is the last section of the report that focuses on data sources, viz. primary and secondary sources, market breakdown and data triangulation, market size estimation, research programs and design, research approach and methodology, and the publishers disclaimer.

Have Any Query? Ask Our Expert @ https://www.verifiedmarketresearch.com/need-customization/?rid=24113

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: sales@verifiedmarketresearch.com

Go here to see the original:
Stem Cell Therapy Market Growth Factors, Rising Trends and Outlook 2020 to 2027 - X Herald

In its newly published report, Global Marketers has provided unique insights about the Animal Stem Cell Therapy Market for the given period. One of the major objectives of this report is to categorize the various dynamics of the market and to offer the newest updates such as mergers and acquisitions, various technological developments, new entrants in the market, which make an impact on different segments of the Animal Stem Cell Therapy market. The report also takes into account the impact of the COVID-19 pandemic on the Animal Stem Cell Therapy market and offers a clear evaluation of the future market demand during the forecast period.

Get a Free Sample Report of Global Animal Stem Cell Therapy Market at:

https://www.globalmarketers.biz/report/life-sciences/global-animal-stem-cell-therapy-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130268#request_sample

The following manufacturers are covered:

Medivet Biologics LLCVETSTEM BIOPHARMAJ-ARMU.S. Stem Cell, IncVetCell TherapeuticsCelavet Inc.Magellan Stem CellsKintaro Cells PowerAnimal Stem CareAnimal Cell TherapiesCell Therapy SciencesAnimacel

This is likely to drive the Global Animal Stem Cell Therapy Market over the forecast period. This research report covers the market landscape and its advancement prediction in the near future. After studying key vendors, the report focuses on the new entrant contributing to the enlargement of the market. Most companies in the Global Animal Stem Cell Therapy Market have currently adopted new technological trends in the market.

Segmentation by Region Of Animal Stem Cell Therapy Are:

Animal Stem Cell Therapy Market Leading Competition:In this section, the report provides information on Competitive situations and trends as well as merger and achievement and expansion, market shares of the top players. Readers could also be provided with production, revenue, and average price shares by Key vendors.

Ask for Discount at:

https://www.globalmarketers.biz/discount_inquiry/discount/130268

Animal Stem Cell Therapy Market Segment by Type, covers:

DogsHorsesOthers

Animal Stem Cell Therapy Market Segment by Applications, covers:

Veterinary HospitalsResearch Organizations

The Animal Stem Cell Therapy market report is the study of various business viewpoints like challenges geographies, divers, restraints, opportunities, and major players. This Animal Stem Cell Therapy research report was aggregated on the grounds of sub-segments and market sections linked to the sector.

Major Highlights of Animal Stem Cell Therapy Market in the Covid-19 pandemic covered in the report:

Market Competition by key manufacturers in the Animal Stem Cell Therapy industry.

Discussed Sourcing strategies, industrial chain information, and downstream buyers data.

Distributors and traders on Animal Stem Cell Therapy marketing strategy analysis focusing on region-wise needs in the COVID-19 pandemic.

Vendors who are providing a wide range of product lines and intensifying the competitive scenario in the Animal Stem Cell Therapy COVID-19 crisis.

Also highlights the key growth sectors of the Animal Stem Cell Therapy market and how they will perform in the coming years.

Inquire Before Buying at:

https://www.globalmarketers.biz/report/life-sciences/global-animal-stem-cell-therapy-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130268#inquiry_before_buying

This Animal Stem Cell Therapy market breakdown also offers the scope of different segments and applications that can in fact impact the market in the future. Thorough information is based on current trends and significant milestones. The Animal Stem Cell Therapy market analysis mentions the volume of sales by region from 2020 to 2024. A thorough evaluation of the limitations included in the market analysis portrays the drivers and gives scope for strategic planning.

Major Highlights:

Detailed overview of parent market

Changing Animal Stem Cell Therapy market dynamics in the industry

exhaustively market segmentation

past, present, and future market size in terms of volume and value

current industry trends and developments

Competitive landscape

Potential and niche segments, geographical regions exhibiting promising growth

Must-have information for market Key vendor to keep going and increase their market footprint

The major key questions addressed through this innovative research report:

Some Points from Table of Content

Global Animal Stem Cell Therapy Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2024

Chapter 1Report Overview

Chapter 2Global Market Growth Trends

Chapter 3Value Chain of Animal Stem Cell Therapy Market

Chapter 4Players Profiles

Chapter 5Global Animal Stem Cell Therapy Market Analysis by Regions

Chapter 6North America Animal Stem Cell Therapy Market Analysis by Countries

Chapter 7Europe Animal Stem Cell Therapy Market Analysis by Countries

Chapter 8Asia-Pacific Animal Stem Cell Therapy Market Analysis by Countries

Chapter 9Middle East and Africa Animal Stem Cell Therapy Market Analysis by Countries

Chapter 10South America Animal Stem Cell Therapy Market Analysis by Countries

Chapter 11Global Animal Stem Cell Therapy Market Segment by Types

Chapter 12Global Animal Stem Cell Therapy Market Segment by Applications

Chapter 13Animal Stem Cell Therapy Market Forecast by Regions (2020-2024)

Chapter 14Appendix

Access full Report Description, TOC, Table of Figure, Chart, etc.at:

https://www.globalmarketers.biz/report/life-sciences/global-animal-stem-cell-therapy-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130268#table_of_contents

See the rest here:
Global Animal Stem Cell Therapy Market Professional Survey 2020 by Manufacturers, Regions, Types and Applications, Forecast to 2024 - The Daily...

CRANFORD, N.J., Oct. 7, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, announced that it has signed an exclusive agreement with Novellus Therapeutics Limited ("Novellus") to license iPSC-derived mesenchymal stem cells (iMSCs), and has created a new subsidiary, NoveCite, that will be focused on developing cellular therapies.

NoveCite has a worldwide exclusive license from Novellus, an engineered cellular medicines company, to develop and commercialize NoveCite mesenchymal stem cells ("NC-iMSCs") to treat acute respiratory conditions with a near term focus on Acute Respiratory Distress Syndrome ("ARDS") associated with COVID-19. Several cell therapy companies using donor-derived MSC therapies in treating ARDS have demonstrated that MSCs reduce inflammation, enhance clearance of pathogens and stimulate tissue repair in the lungs. Almost all these positive results are from early clinical trials or under the emergency authorization program.

NC-iMSCs are the next generation mesenchymal stem cell therapy. They are believed to be differentiated and superior to donor-derived MSCs. Human donor-derived MSCs are sourced from human bone marrow, adipose tissue, placenta, umbilical tissue, etc. and have significant challenges (e.g., variable donor and tissue sources, limited supply, low potency, inefficient and expensive manufacturing). iMSCs overcome these challenges because they:

Globally, there are 3 million cases of ARDS every year out of which approximately 200,000 cases are in the United States. The COVID-19 pandemic has added significantly to the number of ARDS cases. Once the COVID patients advance to ARDS, they are put on mechanical ventilators. Death rate among patients on ventilators can be as high as 50% depending on associated co-morbidities. There are no approved treatments for ARDS, and the current standard of care only attempts to provide symptomatic relief.

"NoveCite iMSCs have the potential to be a breakthrough in the field of cellular therapy for acute respiratory conditions because of the high potency seen in Novellus' pre-clinical studies, and because iMSCs are iPSC-derived, and therefore overcome the manufacturing challenges associated with donor derived cells," said Myron Holubiak, Chief Executive Officer of Citius.

"We are excited to be part of this effort because of the promise to save lives and reduce long term sequelae in patients with devastating respiratory diseases such as ARDS caused by COVID-19," said Dr. Matthew Angel, Chief Science Officer of Novellus. "Our iMSC technology has multimodal immunomodulatory mechanisms of action that make it potentially promising therapy to treat acute respiratory diseases."

About Citius Pharmaceuticals, Inc.

Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit http://www.citiuspharma.com.

About Novellus, Therapeutics, Limited

Novellus is a pre-clinical stage biotechnology company developing engineered cellular medicines using its patented non-immunogenic mRNA high specificity gene editing, mutation-free & footprint-free cell reprogramming and serum insensitive mRNA lipid delivery technologies. Novellus is privately held and is headquartered in Cambridge, MA. For more information, please visit http://www.novellus-inc.com.

About NoveCite iMSC (NC-iMSC)

NoveCite's mesenchymal stem cell therapy product is derived from a human induced pluripotent stem cell (iPSC) line generated using a proprietary mRNA-based (non-viral) reprogramming process. The NC-iMSCs produced from this clonal technique are differentiated from human donor-derived MSCs (bone marrow, placenta, umbilical cord, adipose tissue, or dental pulp) by providing genetic homogeneity. In in-vitro studies, NC-iMSCs exhibit superior potency and high cell viability. NC-iMSCs secrete immunomodulatory proteins that may reduce or prevent pulmonary symptoms associated with acute respiratory distress syndrome (ARDS) in patients with COVID-19. NC-iMSC is an allogeneic (unrelated donor) mesenchymal stem-cell product manufactured by expanding material from a master cell bank.

First generation (human donor-derived) MSCs are isolated from donated tissue followed by "culture expansion". Since only a relatively small number of cells are isolated from each donation, first generation MSCs are increased by growing the cells in culture. Unfortunately, these type of MSCs start to lose potency, and ultimately become senescent. Each donation produces a limited number of MSCs, so a continuous supply of new donors is needed to produce commercial scale. The number and quality of MSCs that can be isolated from different donors can vary substantially.

About Acute Respiratory Distress Syndrome (ARDS)

ARDS is an inflammatory process leading to build-up of fluid in the lungs and respiratory failure. It can occur due to infection, trauma and inhalation of noxious substances. ARDS accounts for approximately 10% of all ICU admissions and almost 25% of patients requiring mechanical ventilation. Survivors of ARDS are often left with severe long-term illness and disability. ARDS is a frequent complication of patients with COVID-19. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.

Safe Harbor

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: the risks associated with developing the NoveCite technology as a treatment for ARDS; risks associated with developing any of our product candidates, including any licensed from Novellus, Inc., including that preclinical results may not be predictive of clinical results and our ability to file an IND for such candidates; our need for substantial additional funds; the estimated markets for our product candidates, including those for ARDS, and the acceptance thereof by any market; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development, including the NoveCite technology; our ability to obtain, perform under and maintain licensing, financing and strategic agreements and relationships; our ability to attract, integrate, and retain key personnel; risks related to our growth strategy; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:Andrew ScottVice President, Corporate Development(O) 908-967-6677 x105(M) 646-522-8410ascott@citiuspharma.com

View original content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-signs-an-exclusive-worldwide-licensing-agreement-with-novellus-therapeutics-for-unique-imsc-therapy-for-acute-inflammatory-respiratory-conditions-including-covid-19-related-acute-respiratory-distress-syndrom-301147409.html

SOURCE Citius Pharmaceuticals, Inc.

Company Codes: NASDAQ-SMALL:CTXR

More:
Citius Pharmaceuticals Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique iMSC-Therapy for Acute Inflammatory...

Abu Dhabi: UAE's Abu Dhabi Stem Cells Centre (ADSCC) is collaborating with Israeli regenerative medicine company, Pluristem, to advance COVID-19 therapies.

In a statement, ADSCC said it was working to administer Pluristem developed PLX cells via a nebuliser to COVID-19 patients. The collaboration will allow ADSCC to expand its stem cell therapy options with the novel PLX cells, while also enabling Pluristem to leverage the ADSCCs nebuliser administration experience to develop a new treatment delivery model for PLX cells.

ADSCC has reported effective usage of nebulisers to treat patients suffering from COVID-19 infection, with stem cells sourced from the patients own blood.

Further discussions are also ongoing to treat chronic Graft Versus Host Disease (cGvHD) a life-threatening immune response to the donors stem cells against the host (patient).

Both projects follow a recently-signed agreement between ADSCC and Pluristem to harness the power of regenerative medicine.

Continued here:
Abu Dhabi Stem Cells Centre collaborating with Israeli firm for COVID-19 therapies - Gulf News

BOSTON, Oct. 1, 2020 /PRNewswire-PRWeb/ --Adapting to the present COVID crisis, this year the 2020 Outsourcing in Clinical Trials USA Conference, one of several international clinical trials supply trade conferences organized by Arena International Events Group each year, adopted a virtual meeting format. The conference, scheduled for September 30-October 1, continued its tradition of bringing together contract research organization suppliers and company sponsors in the clinical trials supply industry to discuss new developments and best practices.

Among the many industry members invited to speak in the event, James L. Sherley, M.D., Ph.D., founder and director of Massachusetts stem cell biotechnology company Asymmetrex, presented on September 30. Dr. Sherley's presentation highlighted a growing new area of the clinical trials supply industry. More and more, the clinical trials supply industry is considering better technology and practices to support stem cell clinical trials and gene therapy clinical trials that utilize advanced therapy medicinal products. In particular, Dr. Sherley discussed the value of implementing new quantification technologies for ATMPs developed with tissue stem cells. He answered the rhetorical question that was the title of his talk "How can we outsource stem cell clinical trials without counting tissue stem cells?" by detailing places in ATMP supply chains where instituting counting technologies would provide significant benefits to the stem-gene clinical trials supply industry and the patients it serves.

Sherley also presented innovation proposals for traditional pharmaceutical and biopharmaceutical clinical trials supply. He described how tissue stem cell counting technologies represented advantages both for discovery of novel drugs and for toxicology evaluations of new drug candidates. A major value presented was the opportunity for drug companies to realize hundreds of millions of dollars in reduced costs each year by using tissue stem cell counting tests for earlier identification of drugs that would fail late in clinical trials because of inducing chronic failure of organs and tissues like the liver and bone marrow. Currently applied animal toxicology studies miss many drugs with this disastrous character. Sherley described how such drugs could be detected in inexpensive cell culture tests by counting how stem cell-specific number and viability changed in their presence.

Though not a main focus of the presentation, Sherley ended his presentation with acknowledgement of Asymmetrex's recent introduction of the first-in-kind technology for counting therapeutic tissue stem cells and determining their dosage. The company holds issued patents for the technology and its use for drug evaluations in both the U.S. and U.K. In August of this year, it published a peer-reviewed report, co-authored with its partner AlphaSTAR Corporation, that describes the new method and its applications for stem cell therapy and drug evaluations. In September, the company was awarded a research and development grant from the National Institutes of Health-National Heart, Lung, and Blood Institute for continued development of the technology and its commercialization. These plans for the company's AlphaSTEM Test tissue stem cell counting technology were recently reported.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. The company's U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of effective use of human adult tissue stem cells for regenerative medicine and drug development. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the "AlphaSTEM Test") for use in stem cell transplantation therapies and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA and the Massachusetts Biotechnology Council.

SOURCE Asymmetrex LLC

Read the rest here:
Asymmetrex Presents the Value of Tissue Stem Cell Counting For Supplying Stem Cell Clinical Trials and Drug Development Clinical Trials - Benzinga

The global platelet rich plasma & stem cell alopecia treatment market report comprises an elaborate executive summary, including a snapshot that provides information on various segments of the market. It also provides information and data analysis of the global market with respect to segments based on treatment, indication, end-user, and region. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. Additionally, the section comprises a competitive matrix and profiles of key market players, along with business overview, to project the competitive landscape of the market. The section also provides presence of key players working in the development of stem cell and platelet rich pharmaceutical products, thereby presenting a thorough analysis of the overall competitive scenario in the global platelet rich plasma & stem cell alopecia treatment market.

This report analyzes the current and future scenario of the global platelet rich plasma & stem cell alopecia treatment market for the period 2018 to 2026. Rise in awareness about platelet rich plasma therapies and stem cell therapies, increase in funding for alopecia treatment research and stem cell research, and increase in the incidence of autoimmune hair loss disorders are likely to be major drivers of the global platelet rich plasma & stem cell alopecia treatment market during the forecast period.

Request Brochure for Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=55800

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment market Witness Most Promising Rise in Demand

The global platelet rich plasma & stem cell alopecia treatment market is expected to reach a value of approximately US$ 450.5 Mn by the end of 2026, expanding at a high single digit CAGR during the forecast period. Factors such as increase in demand for accurate and prompt treatment of alopecia and advancements in platelet rich plasma and stem cell therapies that have revolutionized the diagnostic science are likely to boost the market. Moreover, a rise in awareness about platelet rich plasma therapies and stem cell therapies is expected to drive the global market during the forecast period.

Increased awareness has driven demand for platelet rich plasma therapy & stem cell therapy in the past few years in countries such as Japan, India, Brazil, and Russia and developed regions such as North America and Europe. Additionally, private players are actively promoting the advantages of treatment of alopecia with stem cell therapy across the globe. A rise in the incidence rates of autoimmune hair loss disorders such as alopecia is estimated to boost the platelet rich plasma & stem cell alopecia treatment market. According to the Journal of Clinical, Cosmetic, and Investigational Dermatology, 2015, the lifetime incidence rate of alopecia areata is approximately 2% worldwide. This is expected to propel the market. However, a lack of treatment approval and high cost of alopecia treatment are likely to hinder the growth of platelet rich plasma & stem cell alopecia treatment market.

Request for Analysis of COVID19 Impact on Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=55800

Based on treatment, the global platelet rich plasma & stem cell alopecia treatment market has been segmented into platelet rich plasma therapy and stem cell therapy. The stem cell therapy segment has been further classified into bone marrow treatment and adipose treatment. In terms of indication, the global platelet rich plasma & stem cell alopecia treatment market has been classified into androgenic alopecia, congenital alopecia, cicatricial or scarring alopecia and others. Based on end-user, the global platelet rich plasma & stem cell alopecia treatment market has been divided into hospitals, dermatology clinics, and others. The market size and forecast for each of these segments have been provided for the period 2018 to 2026, along with their respective CAGR for the forecast period 2016 to 2026, considering 2017 as the base year.

Key Players of Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Report:

Major players operating in the global platelet rich plasma & stem cell alopecia treatment market include Kerastem, Eclipse, Regen Lab SA, Stemcell Technologies, Inc., RepliCel Life Sciences, Histogen, Inc., and Glofinn Oy. Key players are focused on research & development of alopecia treatment by investing in platelet rich plasma & stem cell alopecia therapies. Mergers & acquisitions, collaborations, and partnerships are helping companies expand their footprint and further develop effective treatments for alopecia.

Buy Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Report

https://www.transparencymarketresearch.com/checkout.php?rep_id=55800&ltype=S

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

See original here:
Platelet Rich Plasma and Stem Cell Alopecia Treatment Market -Key Players, Size, Growth, Incredible Potential, and Stagnant Progress According to New...

TORONTO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (CB2 or the Company), one of the largest integrative healthcare systems in the United States, is pleased to announce that it has completed the asset acquisition of Maverick County Medical (MCM) in Eagle Pass, Texas. The acquisition of MCM expands the Companys bricks and mortar and telemedicine services to 14 States and adds 10,300 new patients to its current roster of 100,000.

MCM has been operating in Eagle Pass for over 15 years with strong patient retention. Services to patients include primary care, occupational medicine, disease management, minor surgeries, and treatment for auto accident injuries, among others. Services provided by MCM are primarily reimbursed through insurance carriers including Medicare, Medicaid and other commercial payors. MCM also provides services for un-insured patients however representing a smaller proportion of todays revenues.

The Company expects to see continued growth in patient registrations and visits as MCM continues to thrive among the challenges most clinics have faced due to the recent COVID-19 pandemic. Further, the Company will work quickly to expand on the current offering of services by leveraging its current telemedicine infrastructure to provide access to patients across the state of Texas. The Company will also evaluate the current services offered to determine growth in new and complimentary services, add new lines of revenue from insurable services, and expand overall patient care.

Our goal is to provide accessible and affordable healthcare solutions, said Prad Sekar, CEO, CB2 Insights. With the expansion into Texas by way of acquisition of MCM, we welcome a family of practitioners, staff and doctors who align with the direction of our Company, and will be a central point of expansion for our services through telemedicine, subscription services for uninsured patients, and the vision for an integrated National healthcare network.

MCM represents the first acquisition by the Company since its recently announced oversubscribed private placement of CAD 5.13 million in September 2020. The acquisition is also part of a 3-pronged growth model which includes growth from the current infrastructure, new services and acquisitions. The Companys experienced management team continues to develop a robust pipeline of accretive and strategic acquisition targets that are revenue generating, profitable and offer significant opportunities for growth.

The Company paid a total cash consideration of CAD 0.98 million for MCM. Terms of the transaction include a customary transition by the previous owners with 50% of the cash awarded at the signing of the transaction, and 50% due 6 months from the date of completion of the transaction. MCM reported revenues in 2019 of CAD 1.6 million and net income of CAD 0.29 million.

About CB2 Insights

CB2 Insights (CSE:CBII OTCQB:CBIIF) is a healthcare services and technology company, working to positively impact patient health outcomes. The Companies mission to improve the lives of patients through the prevention and treatment of health conditions and using proprietary technology to monitor, assess, and generate insights to help improve patient outcomes. The Company owns and operates a proprietary virtual telehealth platform, and a network of over 30 medical clinics across 13 states in the US, providing integrative, primary and urgent care services to over 100,000 patients annually.

The Company has created works primarily to roster and treat patients seeking traditional and alternative treatments due to the ineffectiveness of conventional medicine, inability to find support through their existing care network, or in some cases, inability to access a primary care network. The Company offers both primary care via a traditional insurable services model and a disruptive low-cost subscription based urgent care offering for patients seeking immediate need to a healthcare provider via telehealth.

The Company differentiates itself by being one of the largest integrative medical practices in the US that owns its own proprietary technology, data analytical assets, and clinical research expertise to support new market expansion, market access, data collection and analysis and drug discovery.

The Company operates a proprietary electronic health record platform Sail (Sail) to document, treat, monitor and report on patient health outcomes. Developed in 2015, Sail is used internally across all of the Companys clinical operations. Sail features a robust telemedicine platform that the Company uses to provide care to its National patient base. To support patient care and positive health outcomes, the Company is also focused on advancing safety and efficacy research surrounding alternative health treatments by monitoring and assessing Real-World Data (RWD) and providing Real-World Evidence (RWE) through our proprietary technology, data analytics, and a full service contract research organization.

For more information please visit http://www.cb2insights.com or contact:

Investor RelationsJonathan L. Robinson CFAOak Hill Financialjrobinson@oakhillfinancial.ca416-669-1001

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in CB2s filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements regarding the Companys unaudited financial results and projected growth.

Although CB2 has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are subject to inconsistent legislation and regulation; change in laws; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and recreational-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. CB2 disclaims any intention or obligation to update or revise such information, except as required by applicable law, and CB2 does not assume any liability for disclosure relating to any other company mentioned herein.

No securities regulator or exchange has reviewed, approved, disapproved, or accepts responsibility for the content of this news release.

Read the original post:
CB2 Insights Announces Acquisition of Texas-based Primary Care Medical & Wellness Clinic with $1.6 million in Revenue and Positive EBITDA -...

For as long as humans have existed, they have told stories to each other. But what about the stories people tell themselves? A breakthrough documentary, Is Your Story Making You Sick? offers a compelling look at how stories define how people see themselves, view relationships, live their lives and manage their health.

Dr. Uday Jani, a respected Milton internist who specializes in integrative medicine, and Lewes chiropractor Dr. Krista Griffin invite the community to watch this award-winning film. An outdoor screening will be held at 7 p.m., Thursday, Oct. 15, at Leftys Alley & Eats, 36450 Plaza Blvd., Lewes. Other screenings set to be held Oct. 8 and 10 in Leftys banquet room are being reworkeddue to changing COVID conditions in the community. A Zoom webinar is being planned; check Dr. Janis website at udayjanimd.com for details on how to participate.

The film features eight people from all walks of life who bravely confront their stories, along with top national mental health experts and a revealing look at narrative therapy exercises and modalities.

This is an important film showing an innovative approach to healing through the real-life journeys of people living with addiction, trauma, depression and anxiety who learn how to confront and ultimately change their stories, said Jani. In this time of COVID anxiety, loneliness and isolation, the baggage people carry may seem heavier than before. But as this documentary shows, there are many tremendously effective modalities that can start the healing.

Jani, who utilizes mind-body practices to care for his patients, credits his fellowship studies at the Arizona Center for Integrative Medicine, and particularly his mentor there, Dr. Ann Marie Chiasson, who appears in the documentary.

It is possible to overcome addiction, PTSD, depression and other stress-related illnesses by re-examining the stories we tell ourselves, said Jani. Finding whats at the root of each individual patients story is how you begin to rewrite the story and begin the process of transcending pain.

The documentary expertly weaves years of filming and research, intensive narrative group therapy, and expertise from leaders in the fields of trauma, addiction, and mindfulness to illustrate the road to meaningful change.

The story problem can manifest in many different ways, and frequently results in a variety of incorrect diagnoses and unneeded drug treatments, said Jani. Learning how to monitor and modify patterns that trigger symptoms allows new patterns to be created and a new story to evolve. The power of healing mind, body and spirit with community involvement has become even more essential during this time of COVID.

Griffin said, Everyone should see this movie. It demonstrates the power childhood emotional traumas have over choices throughout ones life. The message of resilience and overcoming is beautifully encouraging and hopeful.

We so appreciate the swift and enthusiastic participation of Leftys owner DJ Hill, who has graciously made his facility available to the community for viewing this important film, said Jani. He has ensured every protocol, from mask wearing to social distancing, is scrupulously followed to keep us all safe.

The film screenings include a live Q&A immediately following the documentary, with Jani and Griffin joined by integrative health specialist Dr. Carolyn Trasko and clinical psychologist Dr. Richard Todd. Proceeds from ticket sales will benefit the Harry K Foundation, dedicated to defeating childhood hunger in Delaware.

For a preview, watch the trailer at youtu.be/zOpUK50JN1g.

Visit link:
Jani and Griffin to host outdoor documentary screening Oct. 15 at Lefty's - CapeGazette.com

What Is a Holistic Veterinarian, and How to Find the Right One for Your Pet?

These experts are trained in natural remedies such as food, herbal medicine, and acupuncture.

Natural remedies such as food, herbal medicine, and acupuncture aren't just for humans. They are treatments for your dog, cat, or guinea pig, too, and they come from a holistic veterinarian, who uses a combination or conventional medicine and natural remedies to treat your pets' ailments.

But holistic veterinarians do more than use natural remedies. "A holistic veterinarian is looking at the pet as a whole, where everything is connected, versus just treating symptoms," explains holistic veterinarian Dr. Katie Woodley, DVM. They're concerned with sousing out the root cause of a problem, she says, and then treating that underlying issuenot just reducing its symptoms. For example, if your pet has an allergy, a conventional veterinarian might treat the problem with steroids, but the problem could return as soon as steroids are no longer administered, Dr. Woodley says. But a holistic veterinarian would look for the root cause of the allergic reactionsuch food or environmentand seek to resolve the issue in a way that does not come back, she says.

Anna Avdeeva / Getty Images

There's nothing wrong with conventional medicine, of course. Both conventional and holistic "methods have their strengths and weaknesses," says Dr. Gary Richter, DVM, owner of Montclair Veterinary Care and Rover health expert, who practices integrative medicine, which is a combination of both methods.

Related: Try One of These Alternative Treatments for Your Pet's Holistic Health

Both conventional and holistic veterinarians receive the same conventional medicine training, but holistic veterinarians further their education through the study of practices such as food therapy, herbal medicine, acupuncture, homeopathy, aromatherapy, and more, Dr. Woodley explains. Pet parents might seek a holistic veterinarian for a number of reasons, Dr. Richter says: They might prefer a holistic philosophy for their own healthcare, and want their pet to experience the same. Or, he says, they've tried conventional medicine and haven't seen the results they ideally want. A pet that's in pain, for example, may not improve with medicationbut a holistic veterinarian could try acupuncture, supplements, or herbal medicine to aid other medications, Dr. Woodley says.

Other unique treatments and services holistic veterinarians may offer could include chiropractic care, ozone therapy, or homotoxicology, says Dr. Richter, who adds that "some [treatments] are more scientifically based than others and what specific therapies are offered by a holistic veterinarian varies greatly based on their education, experience, and personal philosophy."

To find the best holistic veterinarian for youand for your pet's needsDr. Richter recommends going to the American Holistic Veterinary Medical Association's website, where you can search for holistic veterinarians in their area. There, you'll also be able to see what unique certifications a veterinarian hasso, for example, if you think your pet needs acupuncture, you can filter the results to find holistic veterinarians that provide acupuncture service in your area, Dr. Woodley says. It's always smart to check reviews too, she adds, "to see if other people have found them helpful for the care of their pet." Perusing their website and social media might help you get a sense of their philosophy, she says, and help you to determine "if it resonates with you as a pet parent."

The rest is here:
What Is a Holistic Veterinarian, and How to Find the Right One for Your Pet? - Yahoo Lifestyle

While it may seem like ginger is a recent trend in holistic and alternative treatments, the plant, which originated in Southeast Asia, has been used for medicinal purposes in countries like India and China for centuries. In fact, many Asian households used it to help treat anything from a headache to a sore throat to menstrual cramps long before studies and scientific evidence proved gingers health benefits.

Healthy Brain Foods You Should Be Eating

According to a study discussing the effectiveness of ginger in the journal Integrative Medicine Insights, the anti-nausea properties of ginger come from gingerols, which are natural anti-inflammatory and antioxidant compounds found in raw ginger that activate spice receptors on the tongue.

If you've ever had ginger ale or ginger tea to settle an upset stomach, you already know that ginger can help with nausea and digestive problems. But to get the largest amount of health benefits from ginger, you should be consuming it raw.

Along with its anti-nausea properties, ginger also stimulates gastric emptying, moving things out of the stomach more quickly and thus providing relief to tummy troubles.

Beyond its use for nausea, ginger is also packed with nutrients that benefit both the body and brain andwhile these healing properties are present in many of its forms, you might consider having a few fresh ginger roots on hand.

In 2013, researchers studied the antiviral effects of both fresh and dried ginger on a respiratory virus in human cells. The study indicated that fresh ginger was an effective tool in protecting the respiratory system, while the dried ginger was not.

Raw ginger is a low-cost and easy-to-find natural remedy that you can use to help treat several everyday issues like sore throats and headaches. If youre unsure how to consume raw ginger, there are a few different ways.

The first is to mince raw ginger and blend it up in a healthy fruit smoothie. To lessen the zing, use fruits that have a lot of sweet flavor like fresh mangos. In this recipe for a mango smoothie with turmeric green tea and ginger, matcha powder adds a soft earthiness that tones down the sharp ginger.

Another option is to add a chunk of ginger to a hot cup of tea or hot water. You dont even have to peel it simply place a piece of ginger in your teacup and pour boiling water over it. Add some honey and a squirt of fresh lemon if you like, and youve got the perfect remedy for fall sniffles.

You can also grate some ginger into your favorite comforting or spicy soup. When you grate ginger as opposed to dropping it in raw, the result is milder and much more dispersed. Its a staple in Indian cooking and brings both heat and a slightly spicy, slightly sweet flavor.

If youre more of an amateur baker, you can also add chopped pieces of ginger to muffins or cake batter or try pumpkin desserts with fresh ginger for a zesty fall twist.

But if you dont want to whip up a recipe, you can eat it raw just as is you only need a tiny sliver to chew on. Cut an inch off the ginger root, use a spoon to peel the brown skin off and nibble on it. You can also use a vegetable peeler to shred super thin slices of ginger and let them sit on your tongue before chewing them down for a less pungent experience.

If youre not familiar with storing raw ginger, it can last in the fridge for three to four weeks and even longer in the freezer. Simply place the root in the vegetable drawer or in an eco-friendly produce bag to keep it fresh, and when youre ready to use it, you can use a grater or zester to grate the frozen piece of ginger right in without needing to thaw it.

Visit link:
What Are the Good Benefits of Ginger? - The Daily Meal

Newswise Irvine, Calif. September 30, 2020 In a new study, published in Current Biology, researchers from the University of California, Irvine School of Medicine reveal how subanesthetic ketamine, which is used for pain management and as an antidepressant in humans, is effective in treating adult amblyopia, a brain disorder commonly known as lazy eye.

Our study, demonstrates how a single-dose of subanesthetic ketamine reactivates adult visual cortical plasticity and promotes functional recovery of visual acuity defects resulting from amblyopia, explained Xiangmin Xu, PhD, a professor of anatomy and neurobiology and director of the Center for Neural Circuit Mapping at the UCI School of Medicine.

Subanesthetic ketamine, commonly used to treat depression and pain, evokes rapid and long-lasting antidepressant effects in human patients. There was evidence that ketamine may control how the nervous system makes structural changes in response to internal and external demands, a process called neural plasticity. But, how the drug worked remained elusive, until now.

Our research team showed that ketamine down-regulates NRG1 expression in PV inhibitory cells, resulting in sustained cortical disinhibition to enhance cortical plasticity in adult visual cortex, said Steven F. Grieco, PhD, a postdoctoral scholar in the Xu lab and lead author. Through this neural plasticity-based mechanism, ketamine mediated functional recovery from adult amblyopia. Xin Qiao, PhD, a postdoctoral staff in the Xu lab is a co-first author for the published paper.

Amblyopia is a vision disorder in which the brain fails to process inputs from one eye, favoring the other eye. The condition can result in decreased vision in the affected eye. Each year, between one and five percent of children worldwide, are diagnosed with this condition.

Fast and sustained ketamine actions show promise for therapeutic applications that rely on reactivating adult cortical plasticity. Further testing is needed to determine the full implications of this discovery.

This study was supported in part by grants from the National Institutes of Health.

About the UCI School of Medicine

Each year, the UCI School of Medicine educates more than 400 medical students, and nearly 150 doctoral and masters students. More than 700 residents and fellows are trained at UCI Medical Center and affiliated institutions. The School of Medicine offers an MD; a dual MD/PhD medical scientist training program; and PhDs and masters degrees in anatomy and neurobiology, biomedical sciences, genetic counseling, epidemiology, environmental health sciences, pathology, pharmacology, physiology and biophysics, and translational sciences. Medical students also may pursue an MD/MBA, an MD/masters in public health, or an MD/masters degree through one of three mission-based programs: the Health Education to Advance Leaders in Integrative Medicine (HEAL-IM), the Leadership Education to Advance Diversity-African, Black and Caribbean (LEAD-ABC), and the Program in Medical Education for the Latino Community (PRIME-LC). The UCI School of Medicine is accredited by the Liaison Committee on Medical Accreditation and ranks among the top 50 nationwide for research. For more information, visit som.uci.edu.

Read the original:
New study finds antidepressant drug effective in treating lazy eye in adults - Newswise